Outlook Therapeutics wins FDA appeal, confirms LYTENAVA effectiveness for eye disease

Filed May 26, 2026 · Period ending May 26, 2026 · ~1 min read

Key Changes

• high

  FDA granted appeal after formal dispute, reversing December 2025 rejection letter for LYTENAVA eye treatment. Agency now confirms drug meets effectiveness standards for treating wet age-related macular degeneration.

  Item 8.01 verify on EDGAR →
• high

  FDA directed its ophthalmology division to work with company on final drug labeling, a critical step before approval. This moves LYTENAVA significantly closer to potential market authorization.

  Item 8.01 verify on EDGAR →
• high

  Company plans June 2026 resubmission as Class 1, which typically triggers two-month FDA review. Approval decision could come as early as August 2026 if review proceeds on standard timeline.

  Item 8.01 verify on EDGAR →